12:00 AM
 | 
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avonex interferon beta-1a: Phase IV data

Biogen Idec released 10-year data from the open-label CHAMPIONS study. In 155 evaluable patients, treatment with Avonex immediately upon diagnosis of a clinically isolated syndrome (CIS) in high-risk patients led to a 40% reduction in conversion to clinically definite multiple sclerosis (CDMS) compared with Avonex...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >